GammaDelta Therapeutics Announces Spin-Out Company Formation

GammaDelta Therapeutics has unveiled the formation of a new spin-out company, Adaptate Biotherapeutics, aimed at developing antibody-based therapies that modulate gamma delta T-cells.

In an Oct. 16, 2019 press release, it was revealed that the new spin-out company will build on GammaDelta’s knowledge so that it is possible to regulate gamma delta T-cell activity through the use of therapeutic antibodies with the potential to trigger an immune response against cancer. Particularly, Adaptate Biotherapeutics will develop a number of potential drug targets and antibodies, discovered by GammaDelta, for therapeutic purposes and to advance them into the clinical trial stages. The current chief scientific officer of GammaDelta, Natalie Mount, will move over to the spin-out company, becoming its chief executive officer. 

“[Gamma delta] T-cells have tremendous therapeutic potential that is yet to be fully realised, and our fascinating journey has afforded additional opportunities beyond our main focus on cell therapy,” said Paolo Paoletti, CEO of GammaDelta Therapeutics, in the press release. “Spinning out these activities to create Adaptate Biotherapeutics now enables the deployment of a focussed effort on non-cell therapy.”

“I’m proud to be leading this new company, and excited by the potential we have to expand the therapeutic opportunities of gamma delta T-cells,” added Mount. “Both companies continue to share the same ultimate goal of harnessing the power of these cells to improve the lives of patients, and I look forward to driving Adaptate Biotherapeutics to achieve this goal.”

Source: Adaptate Biotherapeutics